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ABSTRACT 
Lung Cancer, a cancer that forms in tissues of the lung, usually in the cells lining air passages, has traditionally been classified into two major 
types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). About 85 percent of all lung cancers are identified as non-small 
cell, and approximately 75 percent of these are metastatic or advanced at diagnosis. Recent findings have changed our understanding of the 
disease, and today distinct molecular subsets of lung cancer have been identified that can be classified by a biomarker profile of a patient’s 
tumor. In spite of advances in early diagnosis and standard treatment, non-small cell lung cancer is regularly analysed at advanced stages 
and has a poor prognosis. The treatment and prevention of lung cancer are major needs that can most likely be enhanced by a better 
understanding of the molecular process in cancer and development of cancer. However, significant progress is underway in both the 
prevention and treatment of lung cancer. Lung cancer therapy has now emerged as a “role model” for precision cancer medicine. Cytology is 
increasingly being used in the evaluation of lung lesions. There are several potential pitfalls encountered in the evaluation of respiratory 
cytology specimens, making interpretation of respiratory cytology challenging. 
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INTRODUCTION  
The lungs are a pair of sponge-like cone-shaped organs in 
the chest, which are a part of our respiratory system. The 
left lung is smaller because the heart occupies space on the 
left side. Furthermore, the lungs are slightly different on 
each side; the right lung has three lobes, whereas the left 
lung has two lobes. The lungs are covered by a thin 
membranous covering called “pleura,” which protects and 
helps the lungs to move back and forth as they expand and 
contract during breathing. A thin, dome-shaped muscle 
below the lungs, called “diaphragm,” separates the chest 
from the abdomen. The diaphragm moves up and down 
during breathing forcing air in and out of the lungs 1. 
Main function of the lungs is to exchange gases between 
the air we breathe and the blood. When we breathe in 
(inhale), oxygen enters into our body through the lungs 
and when we breathe out (exhale) carbon dioxide is sent 
out of our body. Air enters the lungs through the nose or 
mouth via windpipe (trachea), which divides into the right 
and left lungs. These airways are called “bronchi” (singular, 
bronchus). Inside each lung, the bronchus divides into 
smaller tubes, the “secondary bronchi,” which further sub-
divide into smaller branches called bronchioles. At the end 
of the bronchioles are tiny air sacs known as “alveoli,” 
which receives many tiny blood vessels. These tiny alveoli 
perform the function of exchange of gases 1. 
 
Figure 1: Anatomy of lungs 
Lung cancer appears to arise in the bronchi in response to 
repetitive carcinogenic stimuli, inflammation, and 
irritation. Disruption of cell development occurs in the 
mucosal lining and progresses to elevate or erode the basal 
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membrane. The tumor then spreads throughout the lung 
and will eventually metastasize to the lymph nodes and 
other parts of the body. There are four main histological 
classifications of lung cancer: squamous cell carcinomas, 
adenocarcinomas, small cell carcinomas, and large cell 
carcinoma. Because the behavior and management of squa-
mous cell carcinoma, adenocarcinoma, and large cell 
carcinomas are very similar, they are often grouped 
together as non-small cell lung cancer (NSCLC) in contrast 
to small cell lung cancer (SCLC), which has a distinct 
natural history and management. Squamous cell carcinoma 
is most commonly found in men and shows the strongest 
relationship with smoking. It arises in the larger and more 
central bronchi and tends to spread locally, later 
metastasizing to other types but grows rapidly at its site of 
origin. Adenocarcinoma was previously known as the most 
common type of lung cancer in women and non-smokers; 
however, the incidence of adenocarcinoma has increased 
in the last two decades, and it is now the most common 
histological subtype in both males and females. The reason 
for the increasing incidence of adenocarcinoma is not well 
understood, but may be related to changing patterns of 
smoking. Cell carcinomas are likely to be undifferentiated 
squamous cell and adenocarcinoma. They usually consist 
of large polygonal cells with vesicular nucle 2. 
Lung cancer is the most common cause of cancer mortality 
worldwide, accounting for 25% of all cancer deaths with an 
incidence rate of 1.2 million people per year 3.The vast 
majority (85%) of cases of lung cancer are due to long-
term exposure to tobacco smoke. About 10–15% of the 
cases occur in people who have never smoked. These cases 
are often caused by a combination of genetic factors and 
exposure to radon gas, asbestos, or other forms of air 
pollutants, including second-hand smoke 4. 
PATHOLOGY OF LUNG CANCER  
The most common primary malignant tumors occurring in 
the respiratory tract arise from the endobronchial 
epithelium. They are subdivided into small cell lung 
cancers (+/- 25%) and non-small lung cancers (+/-
75%).These are further subdivided into squamous cell 
carcinoma, adenocarcinoma, and undifferentiated large cell 
carcinoma. The cancer growth frequently leads to 
endobronchial obstruction, which represents the classical 
indication for palliative endobronchial brachytherapy. In 
selected early cases cancer growth is very limited and 
superficial and is confined to the dimensions of the 
bronchial wall. These cases may be considered for 
definitive treatment with curative intent with 
brachytherapy playing a major role, often in combination 
with photodynamic therapy. Lung metastases from other 
primary sites such as e.g. renal cell carcinoma, breast 
cancer, soft tissue sarcoma, osteosarcoma, or malignant 
melanoma only represent an indication for intraluminal 
brachytherapy if there is endobronchial obstruction caused 
by intraluminal tumour growth, which is rather rare 5. 
It is generally accepted that the pathogenesis of human 
cancer involves the accumulation of multiple molecular 
abnormalities over time. Those alterations lead to acquired 
cellular capabilities that can be classified in the following 
six functional sets: a) self-sufficiency in growth signals due 
to mutations in proto- oncogenes, b) insensitivity to 
antiproliferative signals as a result of mutations affecting 
the tumour suppressor genes, c) evading of apoptosis by 
up-regulation of antiapoptotic or down-regulation of 
proapoptotic molecules, d) limitless replicative potential 
due to the activation of telomerase, e) sustained 
angiogenesis and f) capability for tissue invasion and 
capability for dissemination into distant sites (metastasis) 
[6]. Those molecular alterations can occur at the level of 
gene up-regulation or down-regulation, DNA sequence 
changes (point mutations), loss of heterozygosity (i.e., 
deletion of one copy of allelic DNA sequences), DNA 
segment amplification or whole chromosome gains or 
losses with the simultaneous genomic instability and 
alterations in microsatellite DNA 7, 8. 
The carcinogens from the tobacco or other environmental 
pollutants lead to the loss of the 3p21.3 allele in thousands 
of cells on different sites of the respiratory epithelium. 
Later, the tumor suppressor genes located in the 3p21.3 
chromosome arm become haplo-insufficient. The next hit 
occurs in genes that are critical for the cell proliferation, 
such as RB, p53, p16 or other genes either by the 
mutational inactivation or by the promoter 
hypermethylation. That permits a clonal outgrowth of the 
initially transformed cells. Some authors suggest that the 
molecular pathogenesis differs significantly between SCLC 
and NSCLC main tumor types9.It is proposed that during 
the pathogenesis of the SCLC neoplastic cells arise directly 
either from normal or hyperplastic epithelial cells without 
passing through characteristic preneoplastic intermediate 
pathological stages (parallel theory of lung cancer 
pathogenesis). On the contrary, the NSCLC pathogenesis is 
accompanied with sequential morphological changes 10.
 
 
Figure 2: Main molecular abnormalities occurring during lung cancer pathogenesis 
Throat et al                                                                                                 Journal of Drug Delivery & Therapeutics. 2018; 8(6-A):129-134  
ISSN: 2250-1177                                                                                  [131]                                                                                 CODEN (USA): JDDTAO 
RISK FACTORS FOR LUNG CANCER 11, 12 
Tobacco smoking – Smoking causes almost 9 out of 10 
lung cancers. Compared with nonsmokers, smokers are 25 
times more likely to develop lung cancer. Second-hand 
smoking Breathing in other people’s tobacco smoke 
(passive or second-hand smoke) can cause lung cancer. 
People who have never smoked but who have been 
frequently exposed to second-hand smoke are 20–30% 
more likely to develop lung cancer than nonsmokers who 
have not been exposed. People who have never smoked 
and have not been around second-hand smoke have about 
a 0.5% risk of developing lung cancer. 
Exposure to asbestos – People who are exposed to 
asbestos have a greater risk of developing cancer. 
Radon- Radon is a radioactive gas that is produced during 
the breakdown of naturally-occurring uranium in soil and 
rocks, particularly granite. It can pass through from the 
ground into homes and buildings. Exposure to excessive 
levels of radon is thought to be a significant causative 
factor in patients with lung cancer who have never 
smoked. 
Genetic susceptibility-It is thought that some people may 
be more likely to develop lung cancer based on their 
genetic makeup. Having a family history of lung cancer, or 
other types of cancer, increases the risk of developing lung 
cancer to some degree. In people who are genetically 
predisposed to lung cancer, smoking further increases the 
risk. 
Exposure to other elements – Contact with the 
processing of steel, nickel, chrome and coal gas may be a 
risk factor. Exposure to radiation and other air pollution, 
such as diesel particulate matter, also increases the risk of 
lung cancer. 
Personal history – The risk of developing lung cancer is 
increased if you have been previously diagnosed with 
another lung disease such as lung fibrosis, chronic 
bronchitis, emphysema or pulmonary tuberculosis. 
Family history – Having a family member diagnosed with 
lung cancer increases the risk. 
Older age – Lung cancer is most commonly diagnosed in 
people aged 60 years and older, though it can occur in 
younger people. 
DIAGNOSIS OF LUNG CANCER 13,14,15,16 
Chest x-ray: A chest x-ray is painless and can show 
tumours 1 cm wide or larger. Small tumours may not show 
up on an x-ray or may be hidden by other organs within 
the chest cavity. After a chest x-ray, you may need more 
detailed tests. 
CT scan: A CT (computerised tomography) scan uses x-ray 
beams to take many pictures of the inside of your body and 
uses a computer to compile them into one detailed, cross-
sectional picture. It can detect smaller tumours than those 
found by chest x-rays, and provides detailed information 
about the tumour, the lymph nodes in the chest and other 
organs. CT scans are usually done at a hospital or a 
radiology clinic. You may be asked to fast (not eat or drink) 
for several hours before the scan to make the scan pictures 
clearer and easier to read. Before the scan, you will be 
given an injection of dye into a vein in your arm. This dye is 
known as the contrast and it makes the pictures clearer. 
The dye may make you feel hot all over, and leave a bitter 
taste in your mouth, and you may feel a sudden urge to 
pass urine.  The CT scanner is a large, doughnut-shaped 
machine. You will lie flat on a table that moves in and out of 
the scanner. The scan itself takes 10–20 minutes, but you 
will also need to prepare and then wait for the scan. While 
a CT scan can be noisy, it is painless. 
PET scan: A PET (positron emission tomography) scan is a 
specialised imaging test, which is available at most major 
hospitals. It is used to stage lung cancer, usually after the 
diagnosis is confirmed. Before the scan, a small amount of 
radioactive glucose solution will be injected into a vein, 
usually in your arm. This makes cancer cells show up 
brighter on the scan because they take up more of the 
glucose solution than normal cells do. You will be asked to 
sit quietly for 30–90 minutes while the glucose solution 
moves around your body, then you will lie on a table that 
moves through the scanning machine. The scan will show 
‘hot spots’ that have taken up the high levels of radioactive 
glucose. 
Lung function test (spirometry): this test checks how 
well the lungs are working. It measures how much air the 
lungs can hold and how quickly the lungs can be filled with 
air and then emptied. You will be asked to take a full breath 
in and blow out into a machine called a spirometer. 
Sputum cytology: A sputum cytology test examines a 
sample of mucus (sputum) from your lungs. Sputum is 
different to saliva as it contains cells that line the 
respiratory passages. To collect a sample, you will be asked 
to cough deeply and forcefully into a container. This can be 
done in the morning at home. The sample can be 
refrigerated until you take it to your doctor, who will send 
it to a laboratory to check under a microscope for 
abnormal cells. 
Biopsy: If a tumour is suspected after an x-ray or CT scan, 
a sample of tissue will be taken to confirm whether you 
have lung cancer. The sample can be collected in different 
ways. 
CT-guided core biopsy: This is used to obtain cells when 
the tumour is in the outer parts of the lungs. A CT scan will 
be used to guide the needle through your chest wall and 
into position. A small piece of tumour can usually be 
removed with the needle. A core biopsy is done in a 
hospital or radiology clinic. You will be observed for a few 
hours afterwards, as there is a small risk this procedure 
can damage the lung. 
Bronchoscopy: A bronchoscopy allows the doctor to look 
inside the large airways (bronchi). A bronchoscope is 
passed down your nose or mouth, down your windpipe 
(trachea) and into the bronchi. The bronchoscope is a 
flexible tube with a light and lens for viewing. It may feel 
uncomfortable, but it shouldn’t be painful. You will be 
given sedation to help you relax or a general anaesthetic, 
and the back of your throat will be sprayed with a local 
anaesthetic to numb it. If the tumour is near your main 
respiratory tract, the cells can be collected using the 
washing or brushing technique. During ‘washing’, a small 
amount of fluid is injected into the lung and withdrawn for 
further examination. ‘Brushing’ involves the use of a brush-
like instrument to remove some cells from the bronchi. 
Endobronchial ultrasound: An endobronchial ultrasound 
(EBUS) is a type of bronchoscopy that allows the doctor to 
see cancers deeper in the lung. Samples may also be taken 
from a tumour or a lymph node in the middle of the chest 
or next to the airways. In other cases, samples can be taken 
from the outer parts of the lung. 
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Mediastinoscopy: This is not used as often as other biopsy 
methods, but is sometimes used if a sample is needed from 
the area between the lungs (mediastinum). A small cut is 
made in the front of the neck and a rigid tube is passed 
down the outside of the trachea. Some tissue is removed 
from the mediastinal lymph nodes. A mediastinoscopy is 
usually a day procedure but you may need to stay 
overnight in hospital for observation. 
Thoracoscopy: A thoracoscopy is an operation used to 
take a tissue sample (biopsy). It is usually done if other 
tests are unable to provide a diagnosis. For a thoracoscopy 
you will have a general anaesthetic. The surgeon will make 
one or two small cuts in your chest and insert a surgical 
instrument called a thoracoscope, which has a camera 
attached. You will wake up with a drain coming from your 
side and stay in hospital for a few days. 
TREATMENT OF LUNG CANCER 
There are several types of treatment for lung cancer. You 
and your health care team will determine which choice is 
best for you after reviewing the type of lung cancer, the 
stage of your disease, your symptoms, and other health 
problems you may have. Lung cancer treatments are 
continuing to improve as new discoveries are made so it is 
important to thoroughly discuss all your options with your 
clinicians. 
Surgery: Surgery provides the best chance of a cure for 
patients with stage I or stage II NSCLC. It involves removal 
of the tumour through resecting one or more lobes of the 
lung (lobectomy or bi-lobectomy) or through removal of 
the whole lung (pneumonectomy). The surgery is 
challenging and should only be undertaken in a unit with 
an appropriate level of expertise. The postoperative 
mortality rate is about 5% and patients can experience 
significant complications after surgery, including 
haemorrhage, respiratory failure, infection and 
arrhythmias. It is of vital importance, therefore, that 
patients are carefully selected and are fit for surgery17. 
Radiotherapy: Radiotherapy uses x-rays to kill or damage 
cancer cells. It can be used to treat all types of lung cancer. 
It may be offered on its own or in combination with 
surgery or chemotherapy. Radiotherapy with curative 
intent is the choice for patients with stage I to III NSCLC 
who are not suitable for surgery. Traditionally the total 
radiotherapy dose is calculated and the dose is then 
divided into smaller portions known as fractions. These 
fractions are given once daily over three to four weeks. 
Recent research has focused on delivering the fractions 
more quickly in a schedule known as CHART (continuous, 
hyperfractionated, accelerated radiotherapy), CHART has a 
small but significant survival advantage over traditional 
radiotherapy18. 
Chemotherapy: Chemotherapy is the treatment of cancer 
with anti-cancer (cytotoxic) drugs. The aim is to destroy 
cancer cells while causing the least possible damage to 
normal, healthy cells. Chemotherapy is usually delivered 
through an intravenous drip. Each chemotherapy 
treatment is called a cycle and is followed by a rest period 
to give your body time to recover. The number of 
treatments you have will depend on the type of lung cancer 
you have and how well your body is coping with the side 
effects.combination of a single third generation medicine 
(eg, vinorelbine, gemcitabine or docetaxel) plus a 
platinum-based drug (carboplatin or cisplatin).Platinum-
based chemotherapy combinations are the standard first-
line treatment for advanced NSCLC19. 
Lobectomy: A lobectomy, the surgical removal of a single 
lobe, is the optimal procedure for the management of early 
stage disease. For patients who are medically fit for 
surgery, a lobectomy is preferred over a sublobar 
resection20. 
Sublobar resection: A sublobar resection is 
recommended over non-surgical interventions for patients 
with stage I NSCLC who cannot tolerate a lobectomy or 
anatomic pulmonary resection due to co-morbid disease or 
decreased pulmonary function. A sublobar resection can 
either be a segmentectomy, which is removal of one or 
more anatomical segments, or a non-anatomical wedge 
resection. While lobectomy is currently the standard of 
care for all medically fit stage I patients, recent evidence 
suggests that sublobar resection may be appropriate for 
some patients with a small (1 cm or less) peripheral 
nodule, or for patients with bronchioloalveolar carcinoma 
histology 21, 22. 
Targeted therapy: New types of drugs known as targeted 
therapy or personalised medicine target specific mutations 
within cancer cells and often work by blocking cell growth. 
Targeted therapy drugs are generally used for advanced 
NSCLC (stage IV) or if the cancer has come back (recurred). 
Epidermal Growth Factor Receptor (EGFR) Inhibitors: 
Epidermal growth factor receptor, a member of the 
HER/Erb-B family of receptor tyrosine kinases, mediates 
cell proliferation, differentiation, survival, angiogenesis, 
and migration.This molecule consists of an extracellular 
domain that binds EGF, transforming growth factor alpha 
(TGF-a), and other growth factors; a short transmembrane 
region; and an intracellular tyrosine kinase domain. Ligand 
binding leads to homodimerisation of EGFR or 
heterodimerisation of EGFR with another receptor of the 
Erb-B family and phosphorylation of specific EGFR 
tyrosine residues. Tyrosine-phosphorylated receptors then 
recruit intracellular signaling proteins, converting extra-
cellular signals to intra-cellular signal transduction events. 
Epidermal growth factor receptor is expressed more 
abundantly in malignant than in normal tissues, and has 
been shown in 40%-80% of NSCLCs [23, 24].There are two 
main types of EGFR inhibitors that are available currently: 
(i) monoclonal antibodies (MAbs) directed at the extra-
cellular domain of the receptor, and (ii) small molecule 
intra-cellular EGFR tyrosine kinase inhibitors. The MAbs 
include drugs, like cetuximab, panitumumab (ABX-EGF) 
and matuzumab (EMD 72000). The later two are currently 
in early phases of investigation[25]. The kinase inhibitors 
gefitinib and erlotinib have been studied extensively 
throughout the world in different population 
groups.Patient characteristics from these trials that have 
been associated with responsiveness to EGFR inhibitors 
include adenocarcinoma histology, female sex, absence of 
history of smoking, and Asian ethnicity26. 
Anti-EGFR MAbs: Antibodies generally have the 
advantages of less frequent administration, induction of 
receptor down regulation, the potential to engage the host 
immune response in direct tumour cell cytotoxicity, and a 
favourable toxicity profile (notably the absence of 
gastrointestinal adverse effects). Antibodies specific for 
EGFR are among the first targeted therapies to 
demonstrate effectiveness in treating cancer, including 
NSCLC27. 
Cetuximab: The monoclonal antibody, cetuximab, is an 
IgG1 MAb that binds specifically and with high affinity to 
the extra-cellular portion of the EGFR and acts as a 
competitive antagonist, preventing endogenous ligand 
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binding. This EGFR blockade affects all cellular functions 
implicated in tumour biology, such as cell proliferation, cell 
survival, DNA repair, tumour angiogenesis, cell motility, 
and cell invasion. Internalisation of EGFR may lead to 
down regulation of cell surface receptors and reduced 
receptor signaling 28. 
EGFR TKIs: Small-molecule TKIs are another class of 
EGFR-targeted agents. The TKIs can be orally 
administrated, have a rapid onset of action, and potentially 
have better tumour penetration than mAbs.Among drugs 
of this class, the two most extensively evaluated in NSCLC 
are gefitinib and erlotinib. Both have demonstrated single 
agent activity in NSCLC29. 
Gefitinib: Gefitinib, an anilinoquinazoline, was the first 
TKI selective for EGFR evaluated in NSCLC. It is orally 
active and given once daily. Gefitinib Monotherapy, Two 
randomised, double-blind trials of gefitinib monotherapy 
in daily doses of 250 mg or 500 mg given to patients with 
advanced NSCLC who had previously received 
chemotherapy regimens 30. 
Erlotinib Like gefitinib, erlotinib is an orally-active, EGFR-
specific quinazoline TKI that demonstrated anti-tumour 
activity in xenograft models.14,15,18,62 In addition to the 
first-line treatment for advanced pancreatic cancer, 
erlotinib is currently approved for second-line treatment 
of locally advanced or metastatic NSCLC 31. 
EGFR and Tumour Angiogenesis (Combination 
treatment): New blood vessel formation is required for 
the growth and progression of most tumours. The EGFR is 
also involved in angiogenesis: the EGFR ligands, EGF and 
TGF-a, induce angiogenesis, and TGF-a promotes the 
expression of VEGF, which induces vascular growth and 
vascular cell permeability,providing a strong rationale for 
combined anti-VEGF/anti-EGFR therapy. The VEGF 
expression is upregulated in many tumours, resulting in an 
imbalance between pro- and antiangiogenic factors in the 
tumour microenvironment, promoting vascularisation and 
growth32. 
Rexinoid Agonists: Lung cancers are known to be 
defective in retinoic acid signalling with low levels of 
RARba and RXRa. Patients with low levels of RXRa have a 
shorter survival than those with normal levels. Bexarotene 
is a rexinoid agonist that produced long disease 
stabilization (> 3 months in 36%) in Phase I single agent 
trials and produced long time to progression in a 
randomized maintenance study 33. 
Herbal Remedy for Lung Cancer: Medicinal plants play 
an important role in the management of cancer especially 
in developing countries where resources are meager. 
Herbal remedies are focused in the pharmaceutical 
industry to evolve a safe route for liver disorders. 
Therefore, hepatoprotective natural products are, 
Withania somnifera, Pomegranate, Curcuma longa, Green 
tea, Lithosperum radix, Chinies herbs, Juzen-Taiho-
To(Japanes medicine), Tinospora cardifolia, Ziziphus 
nummularia etc.34. 
CONCLUSION  
Lung cancer appears to arise in the bronchi in response to 
repetitive carcinogenic stimuli, inflammation, and 
irritation. Disruption of cell development occurs in the 
mucosal lining and progresses to elevate or erode the basal 
membrane. Tremendous progress in understanding the 
pathogenesis of lung cancer has occurred over the past 
century. There are several types of treatment for lung 
cancer. You and your health care team will determine 
which choice is best for you after reviewing the type of 
lung cancer, the stage of your disease, your symptoms, and 
other health problems you may have.  
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